Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-274495
Filing Date
2023-11-09
Accepted
2023-11-09 16:06:30
Documents
92
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d538891d10q.htm   iXBRL 10-Q 2943293
2 EX-31.1 d538891dex311.htm EX-31.1 10362
3 EX-31.2 d538891dex312.htm EX-31.2 10419
4 EX-32 d538891dex32.htm EX-32 4339
  Complete submission text file 0001193125-23-274495.txt   13826952

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA teva-20230930.xsd EX-101.SCH 93036
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE teva-20230930_cal.xml EX-101.CAL 50951
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE teva-20230930_def.xml EX-101.DEF 594030
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20230930_lab.xml EX-101.LAB 615821
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20230930_pre.xml EX-101.PRE 626957
86 EXTRACTED XBRL INSTANCE DOCUMENT d538891d10q_htm.xml XML 3134076
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16174 | Film No.: 231392341
SIC: 2834 Pharmaceutical Preparations